Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifeprunox in schizophrenia maintenance
NCT00704509Phase 3Terminated
- Sponsor
- Lundbeck
- Start
- Jun 2008
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of bifeprunox in schizophrenia (3 arms), sponsored by Lundbeck. Primary endpoint: Positive and Negative Syndrome Scale at 12 weeks. Started Jun 2008; status: terminated.
02
Drugs
bifeprunox
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00704509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00704509.